Skip to content

Pulsed Radiofrequency of S2-4 Versus Ganglion Impar Neurolysis for Severe Perianal and Perineal Pain in Cancer Patients

Bilateral Pulsed Radiofrequency of Dorsal Root Ganglia of S2-4 Versus Ganglion Impar Neurolysis for Severe Perianal and Perineal Pain in Cancer Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05591430
Enrollment
40
Registered
2022-10-24
Start date
2022-10-28
Completion date
2024-05-30
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia

Brief summary

Perineal pain resulting from malignancy is usually severe. Pain can be related to the malignancy or as a complication related to the treatment. several modalities are adopted to control such pain starting from medical management to interventional pain procedures.

Detailed description

Perineal pain resulting from malignancy is usually severe. Pain can be related to the malignancy or as a complication related to the treatment. several modalities are adopted to control such pain starting from medical management to interventional pain procedures. Ganglion impar block has been traditionally used for treatment of such perineal pain. Radiofrequency of sacral dorsal root ganglia can be used as an alternative for pain control.

Interventions

block of Ganglion Impar by neurolytic drug

PROCEDUREBilateral S2, S3 and S4 Pulsed radiofrequency

Bilateral S2, S3 and S4 Pulsed radiofrequency

Sponsors

National Cancer Institute, Egypt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients aged 18-75 years * ASA II-III with perianal and perineal pain related to cancer

Exclusion criteria

* patient refusal * coagulation defects * abnormal kidney or liver functions * local infection at site of injection

Design outcomes

Primary

MeasureTime frameDescription
Visual analogue scale2 hoursthe score of visual analogue scale score, with minimum score of 0 and maximum of 10, with higher scores meaning more severe pain

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026